Objective: To describe the liver disease epidemiology among HIV-infected individuals in Zambia.
Introduction
In high-income settings advanced liver disease is a leading cause of mortality among HIV-infected individuals, primarily due to chronic viral hepatitis co-infection. In the D:A:D study of HIV-infected patients taking antiretroviral drugs in Europe, Australia, and Argentina, 14.5% of deaths were liver disease-related as a result of decompensated cirrhosis, and/or hepatocellular carcinoma. 1 Among those who died from liver disease, 17% had chronic hepatitis B virus (HBV) and 66% had hepatitis C virus (HCV). 1 In the Multicenter AIDS Cohort Study in the United States, men who were dually HIV-and HBV-infected had 8 times higher liver-related mortality than those with HIV alone. 2, 3 HIV-infected individuals in sub-Saharan Africa (SSA) may be at higher risk of developing liver fibrosis and cirrhosis from various factors. In SSA, the prevalence of HBV co-infection reaches 10-15% in the general population, and three million individuals are estimated to be dually infected with HIV and HBV. 4 In these settings, chronic HBV is most commonly acquired in early childhood and was inconsistently found to be a risk factor for liver fibrosis. 5, 6 Fibrosis may also be caused by environmen-
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This article is protected by copyright. All rights reserved. tal exposure to aflatoxins and by certain traditional herbal medicines. In rural Uganda, for example, HIV-infected patients who reported herbal medicine use had 2-5 fold higher rates of liver fibrosis. 7 Schistosomiasis is also endemic in SSA and contributes to the burden of periportal fibrosis and portal hypertension. 8 Due to limited access to diagnostic tests for liver fibrosis/cirrhosis in SSA, the causes of liver disease are poorly understood among HIV-infected populations. Although the most advanced cases are diagnosed clinically, the diagnosis historically required a liver biopsy, which is unavailable outside of major referral centers due to its invasive nature, the requirement for a pathologist to interpret hepatic histology, and the potential complications. To reduce the need for biopsy, blood and imaging tests for liver fibrosis have been developed, including transient elastography (TE, Fibroscan ® ), which has been used in several recently published studies in Africa 5, 9, 10 and recommended by WHO in management of HBV 11 and HCV. 12 Using TE, we measured liver stiffness in a relatively large cohort of HIVinfected, antiretroviral therapy (ART)-naïve Zambian adults and investigated possible risk factors for liver fibrosis/cirrhosis.
Methods

Study setting and patients
In two public sector HIV treatment facilities in Zambia's capital Lusaka we recruited HIV-infected adults (18+ years old) who were eligible for ART into a prospective cohort study. According to local guidelines at the time, patients were ART eligible if they had WHO clinical stage 3 or 4 disease and/or a CD4+ count of <350 cells/mm 3 prior to April 2014 after which eligibility expanded to all patients with a CD4+ count <500 cells/mm 3 . 13 Patients who intended to transfer care to a facility outside of Lusaka within 12 months of ART initiation were excluded from participation. This study was implemented within the framework of the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA), a large regional network of HIV treatment programs that pools and analyzes standardized and anonymized datasets. 14 
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Laboratory measurements
In addition to WHO staging and CD4+ testing at enrollment, we measured height, weight, ALT, AST, creatinine, and platelet count. Using rapid point-of-care tests in the clinic we screened patients for hepatitis B surface antigen (HBsAg; Determine HBsAg, Alere Inc., Massachusetts, USA) using finger prick sampling and for hepatitis C antibody (Oraquick HCV, Orasure Technologies, Pennsylvania, USA) using an oral swab kit. Patients were defined as HBV co-infected if the HBsAg test was positive.
Among HBV co-infected individuals, we measured hepatitis B e antigen (HBeAg) and HBV DNA levels (Roche COBAS AmpliPrep/COBAS TaqMan HBV Test version 2.0; limit of detection, 20 IU/ml). We also determined HBV genotype using an in-house Sanger sequencing assay. [15] [16] [17] Nucleotide sequences were analyzed with Sequencher version 5.0 (Gene Codes Corporation, Michigan, USA) and the Geno2Pheno (www.geno2pheno.org) platform was used to predict HBV genotypes.
Assessment of liver stiffness
Liver fibrosis/cirrhosis was assessed in non-pregnant patients using TE according to manufacturer guidelines (Echosens, Paris, France). With patients lying supine with their right arm abducted, at least 10 valid liver stiffness measurements (LSM) were made of the right lobe of the liver. Measurements were made by 1 of 3 operators who received manufacturer-recommended training. We classified TE as very reliable if the interquartile range divided by median (IQR/M) was <0.1, reliable if IQR/M was 0.1-0.3, and poorly reliable if IQR/M was >0.3. 18 We defined significant hepatic fibrosis (corresponding to Metavir stages F2-F4) as median LSM >7 kPa and cirrhosis (Metavir stage F4) as median LSM >11 kPa. These thresholds were suggested in the WHO guidelines for treatment of hepatitis B virus in resource-limited settings. 11 In secondary analyses we considered high LSM thresholds (>9.3 kPa for significant fibrosis and >12.3 kPa for cirrhosis) that were used in other liver fibrosis studies in SSA and based on validation studies in Europe and the U.S. 5, 9 Other study procedures Using a standardized questionnaire we screened for potential causes of elevated liver stiffness including anti-tuberculosis treatment, current herbal medicine use, regular exposure to freshwater lakes or rivers (a surrogate for schistosomiasis), and alcohol use. We assessed current and recent alcohol consumption using the World Health Organization's Alcohol Use Disorders Identification Test consumption questions (AUDIT-C), 19 an instrument that has been used in other African settings. 20
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Each alcoholic beverage was standardized to a local beer that contained 10 grams of alcohol per 12ounce bottle. We defined a possible alcohol use disorder as an AUDIT-C score of ≥3 points for women and ≥4 for men. 19 
Statistical analyses
Among patients with a valid TE result, we compared baseline characteristics between HBsAg positive and negative participants using Wilcoxon rank sum tests for continuous variables and Chi square tests for categorical ones. We categorized body mass index as <18.5, 18.5-25, and >25 and CD4+ count as <100, 100-199, 200-350, and >350 cells/mm 3 . We investigated the association between HBsAg-positivity and significant fibrosis and cirrhosis using multivariable logistic regression, adjusted for all factors associated with fibrosis or cirrhosis in univariable analyses as well as those identified a priori from literature review. Among HIV-HBV co-infected patients, we described the proportion with hepatic fibrosis and cirrhosis according to HBV viral load and ALT level. We used Stata version 12 (Statacorp, College Station, Texas) for data analysis.
Results
From October 2013 to August 2014, we enrolled 798 HIV-infected treatment-naïve adults in the cohort study and 653 had TE at enrollment. The main reasons for a missing TE result were pregnancy as a contraindication (n=25), or enrollment at time when the instrument was unavailable (n=118). TE was invalid in two cases with the remaining 651 (82%) comprising the analysis cohort. Patients excluded from the analyses because of unavailability of TE had similar age, sex, WHO clinical stage, HBsAg status, and CD4+ count compared to those who received the test (all P>0.05).
Within the analysis cohort, the median age of participants was 34 years (interquartile range
[IQR] 29-40), 343 (52.7%) were women, and the median CD4+ count was 229 cells/mm 3 (IQR 122-336) at the time of ART initiation. HBsAg-positivity was relatively common (n=98, 12.4%) but antihepatitis C antibody positivity was rare (n=1, <1%). No current or recent alcohol consumption (i.e., AUDIT-C score of 0) was reported by 360 (55.1%), moderate consumption (AUDIT-C of 1-2 for women and 1-3 for men) was reported by 25 (3.8%), and 268 (41.2%) reported levels of drinking consistent with a possible alcohol use disorder (58.9% of men versus 25.2% of women, P<0.001). Current use of at least one herbal medicine was reported by 103 (15.8%) participants. A full description of the characteristics of the analysis cohort is displayed in Table 1 .
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Among HBV co-infected patients, 19 (29.7%) were hepatitis B e antigen positive, the median HBV viral load was 3.7 (2.1-6.4) log 10 IU/ml, and 53.6% had HBV viral loads >2,000 IU/ml. HBV genotype was A1 for 29 patents, E for 28 patients, and 1 patient had mixed infection with A1 and E. Compared to their HBsAg-negative counterparts, HBV co-infected patients were more likely to be male, to have alcohol use disorder, had higher median ALT but similar median CD4+ counts. Age and sex distribution were similar in both study groups (Table 1) Among HBV co-infected patients, significant fibrosis was more common in those with elevated ALT (23.6% versus 8.8%, P=0.083), positive HBeAg (42.1% versus 22.2%, P=0.08), or HBV viral loads >20,000 IU/ml (31.2% versus 20.4%, P=0.32). When stratified by ALT levels (normal or elevated) and HBV viral load (≤20, 20-2,000, or >2,000 IU/ml), we observed a significant trend toward higher liver stiffness level with increases in both (P=0.04; Figure 2 ).
Discussion
Among HIV-infected patients in Lusaka, Zambia, HBsAg-positivity was a strong predictor of liver fibrosis and cirrhosis at the time of ART initiation and this association increased with markers of HBV severity. Increased age, male sex, and advanced clinical stage of HIV infection were also linked with elevated liver stiffness. These data suggest that HBV co-infection should be diagnosed early during HIV care and that interventions to identify and manage liver disease in HIV programs in SSA could be tailored to specific groups.
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Our findings are consistent with those of other African studies. At a public facility in Nigeria, 325
HIV-infected adult patients (including 93 with HIV-HBV) underwent a cross-sectional assessment of liver fibrosis using TE. 5 HIV-HBV co-infected patients had 5 times the odds of significant fibrosis compared to those with HIV alone. Similar to our findings, HBV viral load was a strong correlate of elevated stiffness measurement, supporting recommendations that HIV-HBV patients be treated with ART regimens that contain tenofovir, the most potent anti-HBV drug available. 21 In addition to HBV, we observed that men were more likely to have elevated liver stiffness.
Women may have had relatively lower liver stiffness because of the protective effects of estrogen in hepatic fibrogenesis. 22 Although alcohol abuse disorders were not linked to LSM in the study, men were more likely to report alcohol use and this could explain their doubling of fibrosis compared to women. Worldwide alcohol is a leading cause of cirrhosis; however, in our cohort an elevated AU-DIT-C score was not linked with liver stiffness for several potential reasons. First, in our experience, quantifying an individual's alcohol intake in Zambia can be challenging because the most common form of alcohol, maize/sorghum beer, can have variable alcohol concentration and drinks are shared within a group. 23 Further, in our study, assessment of alcohol use was done at the time of ART initiation and we suspect that many recent drinkers had abstained for a period of weeks to months as they were HIV tested, linked to care, and assessed for ART eligibility. Therefore, the hepatic effects of heavy drinking such as steatohepatitis may have receded prior to our assessment of liver fibrosis.
Despite these results, screening for alcohol use disorders remains an important intervention as heavy drinking was highly prevalent.
This study had a number of strengths. First, we demonstrated the feasibility of screening for liver fibrosis and cirrhosis using TE, a relatively novel non-invasive test that has been used in a very limited number of studies in SSA. 5, 9, 10, 24 Despite limited availability in SSA, WHO guidelines for HBV 11 and 
Our study also had weaknesses. Because of pregnancy and unavailability of TE, nearly 20% of our cohort did not have a baseline assessment of LSM. However, we do not expect this to have significantly biased our analyses as there were no major differences in the baseline characteristics of these patients compared to those analyzed. Although it is widely recommended for liver fibrosis assessment, TE is imperfect and has not been validated in HIV-infected cohorts in SSA. Rather than focus our analysis on the prevalence of fibrosis/cirrhosis, we investigated risk factors for high LSM, considering various thresholds. We believe this approach provided evidence regarding the usefulness of TE in SSA settings. For settings where TE is not available, more investigation is needed into blood indices that depend on low cost tests, such as AST-to-platelet ratio, 6, 26 and GGT-toplatelet ratio. 27 Finally, we did not comprehensively assess patients for other potential causes of liver fibrosis such as hepatosplenic schistosomiasis or aflatoxin exposure.
In summary, among treatment naïve HIV-infected adults in Lusaka, Zambia, HBV co-infection was the most important risk factor for elevated liver stiffness. Liver-related mortality among HIVinfected individuals is often preceded by fibrosis and cirrhosis. Therefore, among HIV-HBV patients, liver fibrosis assessment using TE or other non-invasive tests may be considered a viable technique to optimize care of this at risk group. Alcohol consumption was defined by consumption questions from Alcohol Use Disorders Identification Test (AUDIT-C). No drinking was defined as AUDIT-C score of 0, moderate drinking was AUDIT-C score of 1-2 for women and 1-3 for men, and alcohol use disorder was AUDIT-C score of 3-12 for women and 4-12 for men. 
